DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Xifaxan (Rifaximin) - Published Studies

 
 



Xifaxan Related Published Studies

Well-designed clinical trials related to Xifaxan (Rifaximin)

Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trials. [2014]

[Role of rifaximin in the treatment of colonic diverticular disease]. [Article in Italian] [2012]

Double-blind randomized controlled trial of rifaximin for persistent symptoms in patients with celiac disease. [2011.10]

Rifaximin: new therapeutic indication and future directions. [2011.07]

Efficacy of levofloxacin and rifaximin based quadruple therapy in Helicobacter pylori associated gastroduodenal disease: a double-blind, randomized controlled trial. [2011.06]

Rifaximin treatment for reduction of risk of overt hepatic encephalopathy recurrence. [2011.05]

Rifaximin improves psychometric performance and health-related quality of life in patients with minimal hepatic encephalopathy (the RIME Trial). [2011.02]

Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy. [2011.02]

Rifaximin therapy for patients with irritable bowel syndrome without constipation. [2011.01.06]

Rifaximin therapy for patients with irritable bowel syndrome without constipation. [2011]

Rifaximin for the treatment of hepatic encephalopathy. [2010.12]

A randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of rifaximin for the prevention of travelers' diarrhea in US military personnel deployed to Incirlik Air Base, Incirlik, Turkey. [2010.11]

Clinical trial: the combination of rifaximin with partially hydrolysed guar gum is more effective than rifaximin alone in eradicating small intestinal bacterial overgrowth. [2010.10]

Rifaximin treatment in hepatic encephalopathy. [2010.03.25]

A randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of rifaximin for the prevention of travelers' diarrhea in US military personnel deployed to Incirlik Air Base, Incirlik, Turkey. [2010]

Rifaximin treatment in hepatic encephalopathy. [2010]

A randomized, double-blind, placebo-controlled trial of rifaximin, a nonabsorbable antibiotic, in the treatment of tropical enteropathy. [2009.09]

Antibiotic therapy in small intestinal bacterial overgrowth: rifaximin versus metronidazole. [2009.03]

Rifaximin for maintenance therapy in antibiotic-dependent pouchitis. [2008.06.23]

Rifaximin for the treatment of active pouchitis: A randomized, double-blind, placebo-controlled pilot study. [2007.10]

Rifaximin for the treatment of active pouchitis: A randomized, double-blind, placebo-controlled pilot study. [2007.06.13]

The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. [2006.10.17]

A randomized, double-blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travelers' diarrhea. [2006.06]

Rifaximin, a nonabsorbed oral antibiotic, prevents shigellosis after experimental challenge. [2006.05.01]

Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin. [2006.04.15]

A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. [2006.02]

Rifaximin-based regimens for eradication of Helicobacter pylori: a pilot study. [2006]

Antibacterial chemoprophylaxis in the prevention of traveler's diarrhea: evaluation of poorly absorbed oral rifaximin. [2005.12.01]

An open-label evaluation of rifaximin in the treatment of active Crohn's disease. [2005.08]

Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth. [2005.07.01]

Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study. [2005.06.30]

A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers' diarrhea. [2005.05.17]

Rifaximin in patients with lactose intolerance. [2005.05]

Evaluation of rifaximin, placebo and lactulose in reducing the levels of benzodiazepine-like compounds in patients with liver cirrhosis: a pilot study. [2005]

Influence of rifaximin treatment on the susceptibility of intestinal Gram-negative flora and enterococci. [2004.11]

Enteroaggregative Escherichia coli diarrhea in travelers: response to rifaximin therapy. [2004.02]

Therapy of travelers' diarrhea with rifaximin on various continents. [2003.05]

Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial. [2003.01]

Rifaximin improves symptoms of acquired uncomplicated diverticular disease of the colon. [2003.01]

Rifaximin versus ciprofloxacin for the treatment of traveler's diarrhea: a randomized, double-blind clinical trial. [2001.12.01]

Rifaximin versus chlortetracycline in the short-term treatment of small intestinal bacterial overgrowth. [2000.05]

Evaluation of the efficacy and safety of rifaximin in the treatment of hepatic encephalopathy: a double-blind, randomized, dose-finding multi-centre study. [2000.02]

Effect of rifaximin on intestinal bacterial overgrowth in Crohn's disease as assessed by the H2-Glucose Breath Test. [2000]

A randomized openly comparative study between rifaximin suspension versus rifaximin pills for the eradication of Helicobacter pylori. [1999.05]

Rifaximin: a nonabsorbed antimicrobial in the therapy of travelers' diarrhea. [1998.11]

Rifaximin and Helicobacter pylori eradication. [1997.07]

Rifaximin, a non-absorbable rifamycin, for the treatment of hepatic encephalopathy. A double-blind, randomised trial. [1997]

Efficacy of rifaximin in the treatment of symptomatic diverticular disease of the colon. A multicentre double-blind placebo-controlled trial. [1995.02]

Treatment of pyogenic skin infections with rifaximin cream. [1993.03]

Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy. [1993]

Efficacy of rifaximin on symptoms of uncomplicated diverticular disease of the colon. A pilot multicentre open trial. Diverticular Disease Study Group. [1992.10]

[Chemotherapeutic prophylaxis in the preparation of the large intestine for surgical interventions: rifaximin P.O. vs. cephalosporin I.V.] [1992.03]

Rifaximin versus neomycin on hyperammoniemia in chronic portal systemic encephalopathy of cirrhotics. A double-blind, randomized trial. [1991.05]

Well-designed clinical trials possibly related to Xifaxan (Rifaximin)

Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy. [2014]

Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. [2011.09.07]

Double-blind, placebo-controlled antibiotic treatment study of small intestinal bacterial overgrowth in children with chronic abdominal pain. [2011.04]

Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. [2007.07.18]

Role of gut microflora and probiotic effects in the irritable bowel syndrome. [2006.08]

Mesalazine and/or Lactobacillus casei in preventing recurrence of symptomatic uncomplicated diverticular disease of the colon: a prospective, randomized, open-label study. [2006.04]

Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study. [2005.05]

Efficacy of mesalazine in the treatment of symptomatic diverticular disease. [2005.03]

Acute recurrent diverticulitis is prevented by oral administration of a polybacterial lysate suspension. [2004.06]

Non-absorbable antibiotics for managing intestinal gas production and gas-related symptoms. [2000.08]

Other research related to Xifaxan (Rifaximin)

Prolonged remission from hepatic encephalopathy with rifaximin: results of a placebo crossover analysis. [2015]

Effect of rifaximin, probiotics, and l-ornithine l-aspartate on minimal hepatic encephalopathy: a randomized controlled trial. [2014]

Is rifaximin effective in maintaining remission in Crohn's disease? [2014]

Efficacy of Rifaximin in prevention of recurrence of hepatic encephalopathy in patients with cirrhosis of liver. [2014]

A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy. [2013]

A multicenter, double-blind, randomized, placebo-controlled study of rifaximin for the treatment of bacterial vaginosis. [2013]

Rifaximin vs. conventional oral therapy for hepatic encephalopathy: a meta-analysis. [2012]

A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. [2011.12]

The Efficacy and Safety of Rifaximin for the Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis. [2011.11.01]

Randomised clinical trial: rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy - a double-blind placebo-controlled study. [2011.10]

A randomized, double-blind, pilot study of rifaximin 550 mg versus placebo in the prevention of travelers' diarrhea in Mexico during the dry season. [2011.09]

The role of rifaximin therapy in patients with irritable bowel syndrome without constipation. [2011.08]

Rifaximin for the treatment of acute infectious diarrhea. [2011.07]

A new use for Xifaxan. [2011.07]

Effects of rifaximin treatment and retreatment in nonconstipated IBS subjects. [2011.07]

Probable interaction between warfarin and rifaximin in a patient treated for small intestine bacterial overgrowth. [2011.05]

Meta-analysis: long-term therapy with rifaximin in the management of uncomplicated diverticular disease. [2011.04]

Biologic properties and clinical uses of rifaximin. [2011.02]

[Rifaximin--a non-resorbable antibiotic with many indications in gastroenterology]. [2011.02]

Rifaximin intake leads to emergence of rifampin-resistant staphylococci. [2011.01]

A randomized, double-blind, pilot study of rifaximin 550 mg versus placebo in the prevention of travelers' diarrhea in Mexico during the dry season. [2011]

Efficacy of levofloxacin and rifaximin based quadruple therapy in Helicobacter pylori associated gastroduodenal disease: a double-blind, randomized controlled trial. [2011]

Editorial: rifaximin and minimal hepatic encephalopathy. [2011]

Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy. [2011]

Rifaximin for the treatment of hepatic encephalopathy. [2010.12]

Therapeutic role of rifaximin in inflammatory bowel disease: clinical implication of human pregnane X receptor activation. [2010.10]

Rifaximin Improves Driving Simulator Performance in a Randomized Trial of Patients with Minimal Hepatic Encephalopathy. [2010.09.13]

Efficacy of rifaximin compared with ciprofloxacin for the treatment of acute infectious diarrhea: a randomized controlled multicenter study. [2010.09]

Rifaximin for the treatment of recurrent Clostridium difficile infection after liver transplantation: A case series. [2010.08]

Rifaximin diminishes neutropenia following potentially lethal whole-body radiation. [2010.07]

Rifaximin therapy for metronidazole-unresponsive Clostridium difficile infection: a prospective pilot trial. [2010.07]

Rifaximin: a nonsystemic rifamycin antibiotic for gastrointestinal infections. [2010.07]

Adjunctive antibiotic therapy with rifaximin may help reduce Crohn's disease activity. [2010.04]

Prevention of travelers' diarrhea with rifaximin in US travelers to Mexico. [2010.03.01]

Stability of extemporaneously prepared rifaximin oral suspensions. [2010.02.15]

Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases. [2010.01]

Clinical trial: the combination of rifaximin with partially hydrolysed guar gum is more effective than rifaximin alone in eradicating small intestinal bacterial overgrowth. [2010]

Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases. [2010]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017